GSK is undergoing major operational shifts regarding its sites, including upgrading the Ware facility, opening a new flagship site in Cambridge, and shutting down its main R&D hub in Stevenage.
13 reports, 4 independent
Updated Aug 11
Gone quiet
Reached 11 outlets in its first 24 hours
- Reports
- 13
- Developments
- 3
- Repetition
- 92%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK is undergoing major operational shifts regarding its sites, including upgrading the Ware facility, opening a new flagship site in Cambridge, and shutting down its main R&D hub in Stevenage.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- GSK is moving U.K.-based R&D operations to Cambridge near Addenbrooke's Hospital.Sub-event
- AstraZeneca cancelled its £450m expansion in Liverpool, while GSK announced a £400m investment in a new R&D center and relocated scientists from Stevenage.Sub-event
GSK announces major operational changes: upgrading Ware site, opening flagship site in Cambridge, and closing Stevenage R&D hub.1 source
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
-
Cambridge
city in Cambridgeshire, England
- Linton, an artist, is performing in residences in Cambridge and Hanoi, while working and living in Berlin, and maintains a professional presence on Instagram.
- Advocacy for rail upgrades is underway, with a Fen Line service running between Downham Market and Cambridge. Terry Jermy urged Heidi Alexander to support the necessary infrastructure improvements.
Coverage
Newest first; wire copies grouped- capital.com
- gsk.comGSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK | GSK
- hexham-courant.co.ukGSK to shut Stevenage R&D hub under plans to open new site in Cambridge
- dailymail.comJobs fears as GSK plans to slash billions in costs by embracing AI